Aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zhang, Yi ^a   Li, Yang ^d   Lin, Changwei ^b   Ding, Jie ^c   Liao, Guoqing ^a   Tang, Bo ^d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STRATIFIN; TRANSCRIPTION FACTOR EZH2; BIOLOGICAL MARKER; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN 14 3 3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; TUMOR INVASION; UPREGULATION; CANCER GRADING; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR VOLUME;

14-3-3 PROTEINS; ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; ROC CURVE; TUMOR BURDEN; UP-REGULATION;

EID: 84907199973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107251     Document Type: Article

References (25)

1. Okuda K (2000) Hepatocellular carcinoma. J Hepatol 32:225-237.
2. Kino T, Gragerov A, Valentin A, Tsopanomihalou M, Ilyina-Gragerova G, et al. (2005) Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 79:2780-2787.
3. Laronga C, Yang HY, Neal C, Lee MH (2000) Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275:23106-23112.
4. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B (1999) 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620.
5. Luo J, Feng J, Lu J, Wang Y, Tang X, et al. (2010)Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis. Med Oncol 27:791-797.
6. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, et al. (2000) Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19:5298-5302.
7. Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, et al. (2000) The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 8:174-180.
8. Sewalt RG, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, et al. (1998) Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 18:3586-3595.
9. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039-1043.
10. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874.
11. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754-1758.
12. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, et al. (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882.
13. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-93.
14. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92:1754-1758.
15. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, et al. (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88:873-882.
16. Zhou WH, Tang F, Xu J, Wu X, Feng ZY, et al. (2011) Aberrant upregulation of 14-3-3σ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 11:397.
17. Gheibi A, Kazemi M, Baradaran A, Akbari M, Salehi M (2012) Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: A potential biomarker for detection of breast cancer in patients. Adv Biomed Res 1:80.
18. Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernández JL, et al. (2010) Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 10:217.
19. Hajósi-Kalcakosz S, Dezso K, Bugyik E, Bödör C, Paku S, et al. (2012) Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol 7:86.
20. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92:1754-1758.
21. Pirrotta V (1998) Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 93:333-336.
22. Au SL, Wong CC, Lee JM, Wong CM, Ng IO (2013) EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. PLoS One 8:e68226.
23. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874.
24. Laronga C, Yang HY, Neal C, Lee MH (2000) Association of the cyclindependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275:23106-23112.
25. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606-11611.